ATB-1012
- Generic Name
- ATB-1012
Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes
Phase 3
Recruiting
- Conditions
- Essential HypertensionDiabetes Mellitus, Type 2
- Interventions
- Drug: ATB-1012 placeboDrug: ATB-1013 placeboDrug: ATB-1011 placebo
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Autotelicbio
- Target Recruit Count
- 248
- Registration Number
- NCT05573477
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath